AM-Pharma and Leading Experts Publish Report on State-of-the-Art Clinical Trials in Acute Kidney Injury

/in , /by

Utrecht, The Netherlands, January 26, 2022 – AM Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that its Chief Operating Officer, Juliane Bernholz, PhD, is among the authors of a recently published peer-reviewed article discussing the design and implementation of clinical trials for Acute Kidney Injury (AKI). With representation […]

Read more

AM-Pharma to Participate in Upcoming Investor Conferences

/in , /by

Utrecht, The Netherlands, January 5, 2022 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Erik van den Berg, the Company’s Chief Executive Officer, and Lars Boesgaard, Chief Financial Officer, will participate in the following investor conferences: Kempen’s 40th Annual Life Sciences Virtual Crossover Conference on Thursday, January […]

Read more

AM-Pharma Appoints Alexander Bastian as Vice President Value & Market Access

/in , /by

Utrecht, The Netherlands, 3 November, 2021 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced the appointment of Alexander Bastian as Vice President Value & Market Access, effective immediately. Mr. Bastian joins the company with over 19 years of leadership in product launch and market access strategies from […]

Read more

AM-Pharma Appoints Lars Boesgaard as Chief Financial Officer and Establishes U.S. Affiliate AM-Pharma Inc.

/in , /by

Utrecht, The Netherlands, 15 September, 2021 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced the appointment of Lars R. Boesgaard as Chief Financial Officer (CFO), effective immediately. Mr. Boesgaard’s career spans 25 years and includes CFO roles at public and private companies, where he built experience with […]

Read more

AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan

/in , /by

AM-Pharma to receive EUR 20 million upfront payment, and EUR 30 million related to milestones prior to regulatory submission, and up to EUR 195 million upon submission, NHI price listing and sales milestone payments bringing the overall deal value to EUR 245 million. Kyowa Kirin gains exclusive rights to develop and commercialize ilofotase alfa in […]

Read more

AM-Pharma Appoints Mark Altmeyer as Chairman of its Supervisory Board

/in , /by

Utrecht, The Netherlands, 6 July, 2021 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced the appointment of Mark Altmeyer, MBA, as Chairman of its Supervisory Board. Mr. Altmeyer is a highly successful biopharma executive with decades of relevant strategic, operational, and commercial experience. As Chairman of AM-Pharma’s […]

Read more

AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial

/in , /by

Utrecht, The Netherlands, 1 July 2021 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced the enrollment of the first patient in Japan as part of its ongoing global pivotal Phase III trial, called REVIVAL. The REVIVAL study is evaluating ilofotase alfa, the Company’s proprietary recombinant human alkaline phosphatase, for the treatment of […]

Read more

AM-Pharma Appoints Martijn Negen as VP Commercial Strategy

/in , /by

Utrecht, The Netherlands, 15 June 2021 – AM-Pharma B.V., an emerging leader focused on  developing therapeutics for severe medical conditions, today announced the appointment of Martijn Negen, MSc, MBA, as Vice President for Commercial Strategy. Martijn Negen has over 20 years of experience in pharmaceutical, biotech and diagnostic companies. He joins AM-Pharma from Alexion Pharma, […]

Read more

AM-Pharma Announces Enrollment and Financing of COVID-19 Cohort in Phase III REVIVAL Trial

/in /by

– First patients with COVID-19 enrolled in the REVIVAL Phase III study – COVID-19 patients with sepsis-associated acute kidney injury will be included in an exploratory cohort in the pivotal trial enrolling up to 1,600 SA-AKI patients overall – RVO, an agency of the Dutch Ministry of Economic Affairs and Climate Policy, provides a loan […]

Read more

AM-Pharma Announces Enrollment of the First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury

/in , /by

– Trial to confirm potential of AM-Pharma’s recombinant alkaline phosphatase to reduce mortality, as demonstrated in the Phase II STOP-AKI study – Target enrolment of up to 1,600 SA-AKI patients at ICUs in Europe, United Kingdom and North America   Utrecht, The Netherlands, 12 November 2020 – AM-Pharma B.V., an emerging leader focused on the […]

Read more